G.Barekat Pharm (XTEH:BRKT1) EPS (Diluted) : IRR (TTM As of Mar. 2017)

View and export this data going back to 2017. Start your Free Trial

What is G.Barekat Pharm EPS (Diluted)?

G.Barekat Pharm's Earnings per Share (Diluted) for the six months ended in Mar. 2017 was IRR191.36.

G.Barekat Pharm's EPS (Basic) for the six months ended in Mar. 2017 was IRR191.36.

G.Barekat Pharm's EPS without NRI for the six months ended in Mar. 2017 was IRR4.70.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

G.Barekat Pharm EPS (Diluted) Historical Data

The historical data trend for G.Barekat Pharm's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G.Barekat Pharm EPS (Diluted) Chart

G.Barekat Pharm Annual Data

Trend

Mar16

Mar17

EPS (Diluted)

123.59

191.36

G.Barekat Pharm Semi-Annual Data
	Mar16	Mar17
EPS (Diluted)	123.59	191.36

Competitive Comparison of G.Barekat Pharm's EPS (Diluted)

For the Biotechnology subindustry, G.Barekat Pharm's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

G.Barekat Pharm's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, G.Barekat Pharm's PE Ratio distribution charts can be found below:

* The bar in red indicates where G.Barekat Pharm's PE Ratio falls into.

G.Barekat Pharm EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

G.Barekat Pharm's Diluted EPS for the fiscal year that ended in Mar. 2017 is calculated as

Diluted EPS (A: Mar. 2017 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(1044706	-	0)	/	5459.311
	=	191.36

G.Barekat Pharm's Diluted EPS for the quarter that ended in Mar. 2017 is calculated as

Diluted EPS (Q: Mar. 2017 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(1044706	-	0)	/	5459.311
	=	191.36

G.Barekat Pharm (XTEH:BRKT1) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

G.Barekat Pharm EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of G.Barekat Pharm's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

G.Barekat Pharm (XTEH:BRKT1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » G.Barekat Pharm (XTEH:BRKT1) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 11, 5th Alley, Bucharest Avenue, Argentina Square, Tehran, IRN

Website

http://www.bpharmed.com

G.Barekat Pharm focuses on the introduction of new pharmaceutical fields such as biotechnology, drug delivery which includes nanotechnology, slow release drugs, and new technologies for health, development of cellular molecular industries like tuberculosis, gene therapy, immunotherapy, and tissue technology.

G.Barekat Pharm (XTEH:BRKT1) Headlines

No Headlines